Profile data is unavailable for this security.
About the company
Medtronic Public Limited Company (Medtronic) is a medical technology and services company. The Company develops, manufactures and markets its medical devices and technologies to hospitals, physicians, clinicians and patients in approximately 160 countries. The Company operates in four segments: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group and Diabetes Group. The Cardiac and Vascular Group segment includes Cardiac Rhythm & Heart Failure, Coronary & Structural Heart and Aortic & Peripheral Vascula. Its Minimally Invasive Technologies Group segment includes Surgical Solutions and Patient Monitoring and Recovery. Its Restorative Therapies Group segment includes Spine, Neuromodulation, Surgical Technologies and Neurovascular. Its Diabetes Group segment includes Intensive Insulin Management, Non-Intensive Diabetes Therapies and Diabetes Services & Solutions. The Company's subsidiaries include Medtronic, Inc. and HeartWare International, Inc.
- Revenue in USD (TTM)30.89bn
- Net income in USD4.62bn
- Incorporated2014
- Employees90.07k
- LocationMedtronic PLC20 On Hatch, Hatch Street LowerDUBLIN 2IrelandIRL
- Phone+353 14381700
- Websitehttp://www.medtronic.com/
More ▼
Mergers & acquisitions
| Acquired company | MDT:NYQ since announced | Transaction value |
|---|---|---|
| Titan Spine Inc | 27.55% | -- |
| Advanced Cardiac Therapeutics Inc | 30.24% | -- |
Data delayed at least 15 minutes, as of Dec 13 2019 23:30 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Zimmer Biomet Holdings Inc | 7.93bn | -81.90m | 30.46bn | 19.00k | -- | 2.52 | 33.00 | 3.84 | -0.4475 | -0.4882 | 38.53 | 58.76 | 0.319 | 0.9495 | 6.57 | 417,236.80 | -0.3385 | 1.26 | -0.3865 | 1.39 | 72.56 | 70.96 | -1.06 | 3.93 | 0.5403 | 4.91 | 0.4085 | 66.57 | 1.66 | 11.40 | -168.51 | -- | 8.43 | 3.71 |
| Baxter International Inc | 11.08bn | 1.39bn | 42.87bn | 50.00k | 32.13 | 5.48 | 19.66 | 3.87 | 2.61 | 2.97 | 20.84 | 15.31 | 0.6494 | 3.76 | 6.04 | 221,600.00 | 8.14 | 8.53 | 9.62 | 10.86 | 42.65 | 42.28 | 12.54 | 16.27 | 2.10 | 43.42 | 0.3971 | 32.91 | 5.36 | 3.40 | 8.71 | 35.20 | -14.89 | -17.59 |
| Edwards Lifesciences Corp | 4.15bn | 819.70m | 48.52bn | 12.80k | 60.21 | 12.72 | 53.62 | 11.69 | 3.86 | 3.65 | 19.57 | 18.30 | 0.6963 | 1.78 | 8.36 | 324,343.80 | 13.75 | 16.03 | 16.58 | 19.07 | 74.40 | 74.19 | 19.74 | 23.37 | 2.74 | -- | 0.1348 | 0.00 | 8.37 | 12.72 | -15.92 | 13.66 | 17.03 | -- |
| Boston Scientific Corporation | 10.39bn | 1.03bn | 62.85bn | 32.00k | 61.53 | 6.48 | 31.46 | 6.05 | 0.7329 | 0.7741 | 7.38 | 6.96 | 0.441 | 2.26 | 6.16 | 324,750.00 | 4.38 | 2.81 | 5.46 | 3.50 | 70.69 | 70.48 | 9.93 | 6.08 | 0.7713 | 3.40 | 0.5289 | 0.00 | 8.57 | 6.58 | 66.22 | -- | 11.05 | -- |
| Intuitive Surgical, Inc. | 4.25bn | 1.29bn | 66.99bn | 5.53k | 53.79 | 8.63 | 45.57 | 15.77 | 10.78 | 11.01 | 35.57 | 67.14 | 0.5164 | 2.73 | 6.97 | 768,463.90 | 15.60 | 14.28 | 17.34 | 15.97 | 69.45 | 68.80 | 30.20 | 27.41 | 4.01 | -- | 0.00 | 0.00 | 18.67 | 10.46 | 14.13 | 10.96 | 12.37 | -- |
| Becton Dickinson and Co | 17.29bn | 1.03bn | 72.68bn | 70.09k | 71.52 | 3.45 | 22.14 | 4.20 | 3.76 | 3.94 | 63.21 | 77.95 | 0.3272 | 3.58 | 7.41 | 246,658.00 | 2.24 | 2.79 | 2.55 | 3.22 | 47.93 | 47.27 | 6.84 | 7.20 | 0.7224 | 4.76 | 0.4791 | 72.79 | 8.18 | 15.41 | 29.16 | -2.73 | 7.94 | 7.16 |
| Stryker Corporation | 14.55bn | 1.87bn | 75.97bn | 36.00k | 41.28 | 6.17 | 28.93 | 5.22 | 4.92 | 9.02 | 38.31 | 32.90 | 0.597 | 1.62 | 6.45 | 404,138.90 | 7.66 | 7.63 | 9.18 | 9.39 | 65.70 | 66.24 | 12.83 | 13.07 | 1.35 | -- | 0.4059 | 39.86 | 9.30 | 8.56 | 7.61 | 14.66 | 24.01 | 12.14 |
| Thermo Fisher Scientific Inc. | 25.22bn | 3.56bn | 128.52bn | 70.00k | 36.37 | 4.38 | 22.09 | 5.10 | 8.81 | 8.89 | 62.43 | 73.21 | 0.4511 | 4.45 | 6.12 | 360,285.70 | 6.37 | 4.94 | 7.07 | 5.58 | 44.48 | 45.09 | 14.12 | 11.69 | 1.23 | 8.55 | 0.3675 | 10.80 | 16.45 | 13.22 | 25.62 | 19.02 | 21.83 | 1.92 |
| Medtronic PLC | 30.89bn | 4.62bn | 152.16bn | 90.07k | 33.20 | 3.01 | 20.78 | 4.93 | 3.42 | 3.45 | 22.85 | 37.73 | 0.3448 | 2.40 | 5.21 | 342,962.80 | 5.19 | 4.39 | 5.73 | 4.90 | 69.63 | 69.26 | 15.07 | 14.55 | 2.28 | 10.95 | 0.3357 | 54.46 | 2.02 | 12.44 | -13.80 | 8.66 | 23.42 | 12.30 |
| Abbott Laboratories | 31.36bn | 3.29bn | 152.71bn | 103.00k | 46.68 | 4.80 | 24.19 | 4.87 | 1.85 | 1.85 | 17.63 | 17.99 | 0.4474 | 3.17 | 5.85 | 304,417.50 | 4.70 | 3.63 | 5.65 | 4.37 | 58.64 | 56.39 | 10.50 | 8.09 | 1.12 | 7.04 | 0.3736 | 86.56 | 11.64 | 9.24 | 35.91 | 4.39 | 4.01 | 14.87 |
Data as of Dec 13 2019. Currency figures normalised to Medtronic PLC's reporting currency: US Dollar USD
34.66%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 30 Sep 2019 | 111.62m | 8.33% |
| Wellington Management Co. LLPas of 30 Sep 2019 | 73.09m | 5.45% |
| BlackRock Fund Advisorsas of 30 Sep 2019 | 66.84m | 4.99% |
| SSgA Funds Management, Inc.as of 30 Sep 2019 | 57.30m | 4.28% |
| Massachusetts Financial Services Co.as of 30 Sep 2019 | 54.64m | 4.08% |
| Lazard Asset Management LLCas of 30 Sep 2019 | 28.16m | 2.10% |
| T. Rowe Price Associates, Inc. (Investment Management)as of 30 Sep 2019 | 22.73m | 1.70% |
| Geode Capital Management LLCas of 30 Sep 2019 | 18.46m | 1.38% |
| Northern Trust Investments, Inc.(Investment Management)as of 30 Sep 2019 | 16.80m | 1.25% |
| Columbia Management Investment Advisers LLCas of 30 Sep 2019 | 14.94m | 1.12% |
More ▼
Data from 30 Sep 2019 - 30 Sep 2019Source: FactSet Research Systems Inc.
